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We studied here the independent associations of estimated
glomerular filtration rate (eGFR) and albuminuria with
mortality and end-stage renal disease (ESRD) in individuals
with chronic kidney disease (CKD). We performed a
collaborative meta-analysis of 13 studies totaling 21,688
patients selected for CKD of diverse etiology. After
adjustment for potential confounders and albuminuria,
we found that a 15ml/min per 1.73m2 lower eGFR below
a threshold of 45ml/min per 1.73m2 was significantly
associated with mortality and ESRD (pooled hazard ratios
(HRs) of 1.47 and 6.24, respectively). There was significant
heterogeneity between studies for both HR estimates. After
adjustment for risk factors and eGFR, an eightfold higher
albumin- or protein-to-creatinine ratio was significantly
associated with mortality (pooled HR 1.40) without evidence
of significant heterogeneity and with ESRD (pooled HR 3.04),
with significant heterogeneity between HR estimates. Lower
eGFR and more severe albuminuria independently predict
mortality and ESRD among individuals selected for CKD,
with the associations stronger for ESRD than for mortality.
Thus, these relationships are consistent with CKD stage
classifications based on eGFR and suggest that albuminuria
provides additional prognostic information among
individuals with CKD.
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This manuscript is the fourth in a series of manuscripts to report
the results of collaborative meta-analyses of estimated glomerular
filtration rate (eGFR) and albuminuria on outcomes of chronic
kidney disease (CKD) undertaken by the CKD Prognosis
Consortium. These analyses were conducted in conjunction
with the 2009 Controversies Conference, sponsored by Kidney
Disease Improving Global Outcomes (KDIGO), which sought to
evaluate the current definition and classification of CKD and
propose alternatives. The report of the Consensus Conference is
included in this issue of Kidney International.1
The first three papers in this series dealt with all-cause and
cardiovascular mortality and with kidney outcomes in general
population cohorts and high-risk cohorts.2–4 This paper reports
the results of a collaborative meta-analysis of mortality and end-
stage renal disease (ESRD) in 13 CKD cohorts, including
predominantly individuals with CKD of diverse clinical
diagnoses accompanied by decreased eGFR and elevated levels
of albuminuria, corresponding to microalbuminuria or macro-
albuminuria. We hypothesized a priori that both eGFR and
albuminuria would be associated with these outcomes, indepen-
dent of traditional cardiovascular risk factors and independent of
each other, and despite inclusion of diverse study populations. Of
particular relevance to these cohorts is the question of whether
the severity of albuminuria provides additional prognostic
information among individuals with CKD, over and above
eGFR, as the current classification of CKD does not have separate
stages by severity of albuminuria.1,5 Previous reports of the
associations of eGFR and albuminuria with outcomes in CKD
studies did not use uniform analytic approaches, and most
reports were not powered to evaluate the independent associa-
tions of eGFR and albuminuria with these outcomes.6–8
RESULTS
Characteristics of studies and participants
A total of 21,688 participants from 14 studies are included
in at least one analysis, including 6 randomized controlled
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trials, 4 observational studies of referred patients, and 4
studies of participants identified by laboratory testing
(Table 1 and Supplementary Appendix S1 online).6–18 A
total of 4374 deaths occurred in the 10 studies from which
information on mortality was captured. Of these studies, six
had data on albumin-to-creatinine ratio (ACR), three had
data on protein-to-creatinine ratio (PCR), and one had data
on dipstick proteinuria. The mortality incidence rate varied
dramatically from 19.8 to 254.7 per 1000 person-years. A
total of 4157 ESRD events occurred in the 12 studies from
which such information was captured. Of these studies, six
had data on ACR, five had data on PCR and one had data on
dipstick proteinuria. The ESRD incidence rate varied
markedly from 13.6 to 115.3 per 1000 person-years. The
mean eGFR varied from 22.2 to 69.8ml/min per 1.73m2. The
median ACR varied from 26.5 to 1245.5mg/g and the median
PCR varied from 80.8 to 2337.4mg/g (Table 2).
Independent associations of eGFR and albuminuria with
mortality
The incidence rate of mortality was generally greater in lower
eGFR categories, but there was wide variation in the inci-
dence rate across studies at every eGFR category (Figure 1a).
After adjustment, all eight of the studies included showed
a positive association between lower eGFR category and
mortality (Table 3). Four of the eight studies had a
significantly higher hazard ratio (HR) for an eGFR of
30–44ml/min per 1.73m2 compared with 45–74ml/min per
1.73m2, and seven of eight studies had a significantly elevated
HR for an eGFR of 15–29ml/min per 1.73m2 compared
with 45–74ml/min per 1.73m2. In continuous analyses,
additionally adjusted for category of ACR, PCR, or dipstick
proteinuria, below an eGFR of 45ml/min per 1.73m2, the
association between a 15ml/min per 1.73m2 lower eGFR and
mortality was statistically significant in five of eight studies,
with a pooled HR of 1.47 (95% confidence interval (CI): 1.22,
1.79; Figure 2a). There was significant heterogeneity between
studies in the HR estimates (I2¼ 82.7%; Po0.001).
The incidence rate of mortality also varied within
albuminuria categories, with a higher incidence with higher
albuminuria categories in most studies (Figure 1b). After
adjustment, a higher albuminuria category was also asso-
ciated with the risk of mortality (Table 4). The third category
of albuminuria, compared with the lowest category, had a
statistically significant association with mortality risk in two
of the five studies with ACR, in two of the three studies with
Table 1 | Participating studies and incidence of mortality and end-stage renal disease
Mortality End-stage renal disease
Study design Source/intervention N
Follow-up,
years
No. of
events
Incidence
ratea
Follow-up,
years
No. of
events
Incidence
ratea
Studies with albumin-to-creatinine ratio
British Columbia9 Observational Referred 13,038 2.8 2449 66.1 2.5 2222 68.9
CRIB10 Observational Referred 308 6.1 115 61.4 4.2 149 115.3
Grampian-ACR23 Observational Identified by
laboratory results
208 2.7 94 166.0 — — —
MASTERPLAN12 Clinical trial Nurse practitioner-
aided care
620 4.1 50 19.8 4.1 61 24.8
Nephro Test14 Observational Referred 1021 — — — 2.5 142 55.1
RENAAL8 Clinical trial Losartan 1513 2.8 313 67.2 3.4 341 79.3
Steno17 Observational Clinic 380 8.9 115 33.9 7.5 54 18.6
Overall 17,088 — 3136 — — 2969 —
Studies with protein-to-creatinine ratio
AASK7 Clinical trial, followed
by observational
study
Antihypertensives
and blood pressure
goal
1084 8.7 250 26.4 7.5 311 38.5
Grampian-PCR23 Observational Identified by
laboratory results
159 2.3 94 254.7 — — —
MDRD6 Clinical trial, followed
by observational study
Dietary protein
restriction
839 9.5 208 26.1 6.2 553 105.8
MMKD13 Observational Referred 203 — — — 4.0 73 89.8
REIN15 Clinical trial Ramipril 352 — — — 2.6 81 88.8
REIN 2 (ref. 16) Clinical trial Ramipril 335 — — — 1.9 72 113.0
Overall 2972 — 552 — — 1090 —
Studies with dipstick proteinuria
Kaiser Permanente
Northwest11
Observational Identified by
laboratory results
1628 4.5 686 92.6 4.4 98 13.6
Overall 21,688 — 4374 — — 4157 —
Abbreviations: AASK, African American Study of Kidney Disease and Hypertension; CRIB, Chronic Renal Impairment in Birmingham; MASTERPLAN, Multifactorial Approach and
Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practitioner; MDRD, Modification of Diet in Renal Disease; MMKD, Mild to Moderate Kidney Disease Study;
REIN, Ramipril Efficacy in Nephropathy; REIN 2, Ramipril Efficacy in Nephropathy 2; RENAAL, Reduction of Endpoints in Non-insulin Dependent Diabetes Mellitus with the
Angiotensin II Antagonist Losartan; Steno, Steno Type 1 Diabetes Study.
aPer 1000 person-years.
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PCR, and in one study with dipstick proteinuria. After
additional adjustment for eGFR category, an eightfold higher
ACR was significantly associated with mortality risk in four
of seven studies, and an eightfold higher PCR was
significantly associated with mortality in all three studies
(Figure 2b). The pooled HR for ACR studies (1.36; 95% CI:
1.16, 1.59) was very similar to the pooled estimate for PCR
studies (1.46; 95% CI: 1.28, 1.66), without evidence of
significant heterogeneity overall (I2¼ 39.9%; P¼ 0.10).
Independent associations of eGFR and albuminuria with
ESRD
The incidence rate of ESRD was markedly greater with lower
eGFR categories (Figure 3a). After adjustment, 9 of 11 studies
had a significantly higher HR for an eGFR of 30–44ml/min per
1.73m2 compared with 45–74ml/min per 1.73m2, with a
pooled HR of 2.72 (95% CI: 1.29, 3.37; Table 5). All 11 studies
had a significantly elevated HR for an eGFR of 15–29ml/min
per 1.73m2 compared with 45–74ml/min per 1.73m2.
Table 2 | Baseline characteristics of participating study populations
Mean age,
years (s.d.)
Female,
%
Black,
%
CVD,
%
DM,
%
Smoking,
%
Hypertension,
%
Hypercholes-
terolemia, %
Median ACR/PCR,
mg/g
Mean eGFR ml/min
per 1.73m2 (s.d.)
Studies with albumin-to-creatinine ratio
British Columbia 68.5 (13.9) 44.8 0.5 23.5 32.4 5.4 41.1 — 94.6 34.9 (17.9)
CRIB 61.7 (14.2) 34.1 5.8 45.5 17.2 13.3 90.6 — 467.2 22.2 (10.6)
Grampian-ACR 73.0 (11.4) 56.4 0 24.2 8.5 61.6 59.5 — 26.5 34.6 (5.8)
MASTERPLAN 60.5 (12.4) 31.0 2.7 30.2 24.3 20.2 95.4 18 119.1 36.3 (13.2)
Nephro Test 59.6 (15.0) 31.7 9.6 16.0 26.0 10.0 88.7 16.6 77.6 41.1 (20.1)
RENAAL 60.2 (7.4) 36.8 15.2 35.0 100 18.1 96.4 — 1245.5 39.8 (12.3)
Steno 42.6 (10.8) 38.1 0 10.2 100 51.9 82.2 36.9 498.0 69.8 (27.5)
Studies with protein-to-creatinine ratio
AASK 54.6 (10.7) 38.8 100.0 51.6 0 29.3 100 55.6 80.8 42.5 (13.2)
Grampian-PCR 73.4 (14.8) 61.6 0 17.0 2.5 55.4 52.8 — 300.9 34.6 (6.2)
MDRD 51.7 (12.4) 39.5 7.9 9.6 5.1 16.6 86.2 23.0 268.5 32.6 (12.3)
MMKD 46.4 (12.3) 34.0 0 12.3 0 21.7 89.2 38.4 1035.0 43.4 (26.7)
REIN 49.5 (13.6) 23.6 0.6 0 7.7 18.2 86.4 — 2337.4 42.9 (18.5)
REIN 2 54.2 (15.0) 25.1 0 0 5.1 16.1 73.1 — 1875.3 31.0 (16.7)
Studies with dipstick proteinuria
Kaiser Permanente
Northwest
71.79 (9.73) 56.0 3.1 44.8 38.8 12.8 92.9 26.0 — 45.7 (10.5)
Abbreviations: AASK, African American Study of Kidney Disease and Hypertension; CRIB, Chronic Renal Impairment in Birmingham; MASTERPLAN, Multifactorial Approach and
Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practitioner; MDRD, Modification of Diet in Renal Disease; MMKD, Mild to Moderate Kidney Disease Study;
REIN, Ramipril Efficacy in Nephropathy; REIN 2, Ramipril Efficacy in Nephropathy 2; RENAAL, Reduction of Endpoints in Non-insulin Dependent Diabetes Mellitus with the
Angiotensin II Antagonist Losartan; Steno, Steno Type 1 Diabetes Study.
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Figure 1 |Crude incidence rate of mortality by category of estimated glomerular filtration rate and category of albuminuria. Crude
incidence rate of mortality (per 1000 person-years) by (a) category of estimated glomerular filtration rate and (b) category of albuminuria.
Solid lines represent studies that assessed albuminuria using albumin-to-creatinine ratio (categories:o30, 30–299, 300–999, andX1000mg/
g). Dashed lines represent studies that assessed albuminuria using protein-to-creatinine ratio (categories: o50, 50–499, 500–1499, and
X1500mg/g). Dotted lines represent studies that assessed albuminuria using dipstick protein (categories: /±, þ , þ þ , andXþ þ þ ).
Points withp5 participants are excluded. AASK, African American Study of Kidney Disease; CRIB, Chronic Renal Impairment in Birmingham;
Grampian-ACR, Grampian albumin-to-creatinine ratio; Grampian-PCR, Grampian protein-to-creatinine ratio; Kaiser NW, Kaiser Permanente
Northwest; MASTERPLAN, Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of Nurse Practitioners;
MDRD, Modification of Diet in Renal Disease; RENAAL, Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan; Steno,
Steno Type 1 Diabetes Study.
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In continuous analyses, additionally adjusting for ACR, PCR,
or dipstick proteinuria category as appropriate, below an eGFR
of 45ml/min per 1.73m2, the association between a 15ml/min
per 1.73m2 lower eGFR and ESRD was statistically significant
in all 12 studies (Figure 4a). Each 15ml/min per 1.73m2 lower
eGFR was associated with a 6.24-fold (95% CI: 4.84, 8.05)
higher risk of ESRD after adjustment for albuminuria and
other covariates. There was significant heterogeneity between
studies in the HR estimates (I2¼ 87.9%; Po0.001).
The incidence rate of ESRD was also markedly greater with
higher albuminuria categories (Figure 3b). The association of
higher albuminuria category and risk of ESRD remained
strong after adjustment (Table 6). The third category of
albuminuria, compared with the lowest category, had a
statistically significant association with ESRD risk in all four
studies with ACR, in two of three studies with PCR, and in
one study with dipstick proteinuria. In continuous analyses,
additionally adjusted for eGFR splines, an eightfold higher
ACR or PCR was significantly associated with ESRD risk in
all 11 studies (Figure 4b). The pooled HR for ACR studies
(2.92; 95% CI: 1.96, 4.35) was similar to the pooled estimate
for PCR studies (3.42; 95% CI: 1.84, 6.37). In analyses
Table 3 | Adjusted hazard ratio (95% confidence interval) for mortality, by estimated glomerular filtration rate categorya
Estimated glomerular filtration rate (ml/min per 1.73m2)
45–74 30–44 15–29 o15
Studies with albumin-to-creatinine ratio
British Columbia Reference 1.40 (1.20, 1.62) 3.06 (2.66, 3.52) 4.07 (3.42, 4.84)
CRIB Reference 1.18 (0.14, 9.65) 1.93 (0.24, 15.32) 3.39 (0.43, 26.88)
MASTERPLAN Reference 1.32 (0.54, 3.20) 2.62 (1.11, 6.21) 4.49 (1.08, 18.66)
RENAAL Reference 1.13 (0.84, 1.50) 1.95 (1.43, 2.66) —
Steno Reference 1.46 (0.80, 2.68) 2.78 (1.48, 5.19) 5.90 (2.33, 14.96)
Studies with protein-to-creatinine ratio
AASK Reference 1.66 (1.25, 2.20) 1.55 (1.10, 2.19) 6.28 (0.85, 46.44)
MDRD Reference 1.75 (1.10, 2.77) 1.79 (1.13, 2.85) 1.68 (0.79, 3.57)
Studies with dipstick proteinuria
Kaiser Permanente Northwest Reference 1.24 (1.05, 1.47) 2.41 (1.94, 2.99) —
Overall Reference 1.35 (1.23, 1.49) 2.25 (1.81, 2.79) 3.74 (2.69, 5.20)
Abbreviations: AASK, African American Study of Kidney Disease and Hypertension; CRIB, Chronic Renal Impairment in Birmingham; MASTERPLAN, Multifactorial Approach and
Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practitioner; MDRD, Modification of Diet in Renal Disease; RENAAL, Reduction of Endpoints in Non-insulin
Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan; Steno, Steno Type 1 Diabetes Study.
aAdjusted for age, sex, race, previous cardiovascular disease, smoking status, diabetes mellitus, systolic blood pressure, and serum total cholesterol concentration.
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Figure 2 | Forest plot of adjusted hazard ratio for mortality associated a 15ml/min per 1.73m2 lower estimated glomerular
filtration rate and an eightfold higher albumin-to-creatinine ratio or protein-to-creatinine ratio. Forest plot of adjusted hazard ratio
for mortality associated with (a) a 15ml/min per 1.73m2 lower estimated glomerular filtration (eGFR) rate (below an eGFR of 45ml/min per
1.73m2) and (b) an eightfold higher albumin-to-creatinine ratio or protein-to-creatinine ratio. The models are adjusted for age, sex, race,
previous cardiovascular disease, smoking status, diabetes mellitus, systolic blood pressure, serum total cholesterol concentration, and
albuminuria (a) or eGFR splines (b). AASK, African American Study of Kidney Disease; CI, confidence interval; CKD, chronic kidney disease;
CRIB, Chronic Renal Impairment in Birmingham; Grampian-ACR, Grampian albumin-to-creatinine ratio; Grampian-PCR, Grampian protein-to-
creatinine ratio; Kaiser NW, Kaiser Permanente Northwest; MASTERPLAN, Multifactorial Approach and Superior Treatment Efficacy in Renal
Patients with the Aid of Nurse Practitioners; MDRD, Modification of Diet in Renal Disease; RENAAL, Reduction of Endpoints in NIDDM with
the Angiotensin II Antagonist Losartan; Steno, Steno Type 1 Diabetes Study.
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combining studies with ACR and PCR, an eightfold higher
ACR or PCR was associated with a 3.04-fold (95% CI: 2.27,
4.08) higher risk of ESRD after adjustment for eGFR and
other covariates. There was evidence of significant hetero-
geneity between ACR studies and between PCR studies and
overall (I2¼ 93.6%; Po0.001).
DISCUSSION
In this meta-analysis of 13 cohorts, including 21,688
individuals selected because of CKD, we found that lower
eGFR and higher albuminuria were each independently
associated with mortality and ESRD. Both eGFR and
albuminuria were more strongly associated with ESRD than
Table 4 | Adjusted hazard ratio (95% confidence interval) for mortality, by albuminuria categorya
Albumin-to creatinine ratio (mg/g)
o30 30–299 300–999 X1000
British Columbia Reference 1.49 (1.26, 1.77) 2.42 (2.09, 2.81) 3.01 (2.51, 3.62)
CRIB Reference 1.65 (0.83, 3.27) 2.15 (1.05, 4.40) 3.56 (1.80, 7.02)
Grampian-ACR Reference 1.14 (0.05, 27.74) 14.91 (0.60, 369.78) 43.91 (1.90, 1014.98)
MASTERPLAN Reference 1.12 (0.58, 2.14) 0.53 (0.19, 1.46) 1.10 (0.41, 2.90)
Steno Reference 2.39 (0.96, 5.93) 1.95 (0.81, 4.69) 2.32 (0.94, 5.76)
Overall Reference 1.50 (1.28, 1.75) 1.85 (1.08, 3.16) 2.73 (1.74, 4.26)
Protein-to-creatinine ratio (mg/g)
o50 50–499 500–1499 X1500
AASK Reference 1.82 (1.35, 2.45) 1.93 (1.30, 2.87) 2.60 (1.54, 4.40)
Grampian-PCR Reference 0.53 (0.22, 1.27) 0.99 (0.40, 2.45) 0.73 (0.25, 2.14)
MDRD Reference 0.99 (0.52, 1.88) 2.17 (1.06, 4.46) 1.80 (0.85, 3.80)
Overall Reference 1.08 (0.54, 2.18) 1.81 (1.30, 2.53) 1.72 (0.90, 3.29)
Dipstick category
/± + ++ +++
Kaiser Permanente Northwest Reference 1.46 (1.16, 1.82) 1.58 (1.28, 1.95) 1.98 (1.48, 2.64)
Overall Reference 1.46 (1.24, 1.71) 1.80 (1.38, 2.35) 2.26 (1.68, 3.04)
Abbreviations: AASK, African American Study of Kidney Disease and Hypertension; CRIB, Chronic Renal Impairment in Birmingham; MASTERPLAN, Multifactorial Approach and
Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practitioner; MDRD, Modification of Diet in Renal Disease; Steno, Steno Type 1 Diabetes Study.
aAdjusted for age, sex, race, previous cardiovascular disease, smoking status, diabetes mellitus, systolic blood pressure, and serum total cholesterol concentration.
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Figure 3 |Crude incidence rate of end-stage renal disease by category of estimated glomerular filtration rate and category of
albuminuria. Crude incidence rate of end-stage renal disease (ESRD; per 1000 person-years) by (a) category of estimated glomerular
filtration rate and (b) category of albuminuria. Solid lines represent studies that assessed albuminuria using albumin-to-creatinine ratio
(categories:o30, 30–299, 300–999, andX1000mg/g). Dashed lines represent studies that assessed albuminuria using protein-to-creatinine
ratio (categories:o50, 50–499, 500–1499, andX1500mg/g). Dotted lines represent studies that assessed albuminuria using dipstick protein
(categories: /±, þ , þ þ , Xþ þ þ ). Points with p5 participants are excluded. AASK, African American Study of Kidney Disease; CRIB,
Chronic Renal Impairment in Birmingham; Kaiser NW, Kaiser Permanente Northwest; MASTERPLAN, Multifactorial Approach and Superior
Treatment Efficacy in Renal Patients with the Aid of Nurse Practitioners; MDRD, Modification of Diet in Renal Disease; MMKD, Mild to
Moderate Kidney Disease; REIN, Ramipril Efficacy in Nephropathy; REIN 2, Ramipril Efficacy in Nephropathy 2; RENAAL, Reduction of
Endpoints in NIDDM with the Angiotensin II Antagonist Losartan; Steno, Steno Type 1 Diabetes Study.
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with mortality in these cohorts of individuals with CKD. To
our knowledge, this represents the largest and most general-
izable study of CKD populations in which these independent
associations have been explored, and confirms the strong and
independent relationship of higher level of albuminuria and
lower levels of eGFR with mortality and ESRD across a wide
Table 5 | Adjusted hazard ratio (95% confidence interval) for end-stage renal disease, by estimated glomerular filtration rate
categorya
Estimated glomerular filtration rate (ml/min per 1.73m2)
45–74 30–44 15–29 o15
Studies with albumin-to-creatinine ratio
British Columbia 1.0 (reference) 1.90 (1.54, 2.35) 8.34 (6.90, 10.07) 25.97 (21.24, 31.75)
MASTERPLAN 1.0 (reference) 2.51 (0.28, 22.51) 40.66 (5.57, 296.57) 203.60 (25.68, 1614.08)
NephroTest 1.0 (reference) 3.75 (1.41, 9.96) 14.67 (5.88, 36.61) 75.80 (29.73, 193.26)
RENAAL 1.0 (reference) 2.66 (1.85, 3.82) 9.33 (6.50, 13.40) —
Steno 1.0 (reference) 4.17 (1.89, 9.18) 13.08 (6.05, 28.28) 156.93 (34.44, 715.10)
Studies with protein-to-creatinine ratio
AASK 1.0 (reference) 3.49 (2.49, 4.88) 12.24 (8.88, 17.02) 118.85 (27.53, 513.09)
MDRD 1.0 (reference) 2.68 (1.92, 3.73) 6.75 (4.87, 9.34) 27.35 (17.85, 41.90)
MMKD 1.0 (reference) 9.34 (2.10, 41.52) 21.25 (5.01, 90.05) 121.44 (28.12, 524.42)
REIN 1.0 (reference) 3.69 (1.67, 8.14) 11.13 (5.27, 23.49) 63.43 (20.61, 195.19)
REIN 2 1.0 (reference) 1.44 (0.30, 6.91) 8.59 (2.06, 35.85) 27.37 (6.22, 120.48)
Studies with dipstick proteinuria
Kaiser Permanente Northwest 1.0 (reference) 2.14 (1.29, 3.55) 15.08 (9.24, 14.60) —
Overall 1.0 (reference) 2.72 (2.19, 3.37) 10.21 (8.36, 12.46) 51.48 (31.95, 82.97)
Abbreviations: AASK, African American Study of Kidney Disease and Hypertension; MASTERPLAN, Multifactorial Approach and Superior Treatment Efficacy in Renal Patients
with the Aid of a Nurse Practitioner; MDRD, Modification of Diet in Renal Disease; MMKD, Mild to Moderate Kidney Disease Study; REIN, Ramipril Efficacy in Nephropathy; REIN
2, Ramipril Efficacy in Nephropathy 2; RENAAL, Reduction of Endpoints in Non-insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan; Steno, Steno
Type 1 Diabetes Study.
aAdjusted for age, sex, race, previous cardiovascular disease, smoking status, diabetes mellitus, systolic blood pressure, and serum total cholesterol concentration.
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Figure 4 | Forest plot of adjusted hazard ratio for end-stage renal disease associated with a 15ml/min per 1.73m2 lower estimated
glomerular filtration rate and an eightfold higher albumin-to-creatinine ratio or protein-to-creatinine ratio. Forest plot of adjusted
hazard ratio for end-stage renal disease associated with (a) a 15ml/min per 1.73m2 lower estimated glomerular filtration rate (below an
eGFR of 45ml/min per 1.73m2) and (b) an eightfold higher albumin-to-creatinine ratio or protein-to-creatinine ratio. The models are
adjusted for age, sex, race, previous cardiovascular disease, smoking status, diabetes mellitus, systolic blood pressure, serum total
cholesterol concentration, and albuminuria (a) or eGFR splines (b). AASK, African American Study of Kidney Disease; CI, confidence interval;
CRIB, Chronic Renal Impairment in Birmingham; Kaiser NW, Kaiser Permanente Northwest; MASTERPLAN, Multifactorial Approach and
Superior Treatment Efficacy in Renal Patients with the Aid of Nurse Practitioners; MDRD, Modification of Diet in Renal Disease; MMKD, Mild
to Moderate Kidney Disease; REIN, Ramipril Efficacy in Nephropathy; REIN 2, Ramipril Efficacy in Nephropathy 2; RENAAL, Reduction of
Endpoints in NIDDM with the Angiotensin II Antagonist Losartan; Steno, Steno Type 1 Diabetes Study.
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range of clinical settings. The use of a uniform analysis plan
also allows for comparisons of the magnitude of the
associations across the studies included.
Compared with an eGFR of 45–74ml/min per 1.73m2,
progressively lower eGFR was associated with progressively
greater risk of death and ESRD. The range of eGFR in the
selected reference group was necessarily broad to enable
analyses, and this precludes a precise determination of the
level of eGFR below which risk begins increasing. Statements
about subdividing CKD stage 3 are better addressed in higher
GFR populations. All CKD studies had data below an eGFR
of 45ml/min per 1.73m2, in which each 15ml/min per
1.73m2 lower eGFR was associated with a 47% higher risk of
death and a sixfold higher risk of ESRD after adjustment for
albuminuria. These results are consistent with the use eGFR
stages in classification of CKD. Similarly, the relatively low
number of participants and few events among individuals
with negative dipstick results precluded separating negative
dipstick from trace proteinuria. Including trace proteinuria
in the reference group would result in lower HRs for þ ,
þ þ , and þ þ þ categories than would result from using
only negative proteinuria as the reference group. Future
studies should explore the clinical implications of trace
dipstick proteinuria among individuals with known CKD.
We also found that higher albuminuria was associated
with greater risk of death and strongly associated with greater
risk of ESRD. The risk increased progressively with every
higher level of albuminuria, and the associations were similar
for studies using ACR, PCR, or dipstick proteinuria. An
eightfold higher ACR or PCR was associated with an
estimated 40% higher risk of death and an estimated
threefold higher risk of ESRD after adjustment for eGFR.
The current CKD classification system does not discriminate
by severity of albuminuria among individuals with CKD.19
These results suggest that adding data on the presence and
severity of albuminuria to eGFR stages provides more
prognostic information than the current classification system.
This may be especially true for predicting the risk of ESRD.
There were no substantial differences in the associations of
ACR or PCR with either death or ESRD, suggesting that each
measure provides useful prognostic information of broadly
equal importance.
The associations of lower eGFR with higher risk of
outcomes remained after adjustment for severity of albumi-
nuria and, likewise, the associations of higher albuminuria
remained after adjustment for eGFR. These results demon-
strate that both lower eGFR and higher albuminuria predict
mortality and ESRD, independent of one another.
There was a wide variation in the incidence rates for
death and ESRD across the cohorts included in this meta-
analysis, presumably reflecting variation in definition of
CKD, causes and pathology of kidney disease, range in eGFR
and albuminuria, comorbid conditions, and other eligibility
criteria. We evaluated statistical heterogeneity using the
I2 statistic, which reflects the variability among effect sizes
due to between-study differences as a percentage of the total
variability. The within-study variation is relatively small,
because the sample sizes of the studies included are relatively
large. Thus, the percentage of total variability that is due to
between-study variation is relatively large, but does not
Table 6 | Adjusted hazard ratio (95% confidence interval) for end-stage renal disease, by albuminuria categorya
Albumin-to-creatinine ratio (mg/g)
o30 30–299 300–999 X1000
British Columbia Reference 2.42 (1.80, 3.26) 7.58 (5.83, 9.86) 12.91 (9.82, 16.95)
CRIB Reference 9.78 (2.35, 40.63) 16.39 (3.95, 68.02) 29.72 (7.18, 123.10)
MASTERPLAN Reference 4.14 (1.22, 14.04) 5.28 (1.49, 18.72) 18.87 (5.57, 63.91)
NephroTest Reference 2.55 (1.26, 5.13) 10.40 (5.31, 20.37) 21.38 (10.86, 42.08)
Overall Reference 2.87 (1.91, 4.34) 7.96 (6.27, 10.09) 14.61 (11.16, 19.13)
Protein-to-creatinine ratio (mg/g)
o50 50–499 500–1499 X1500
AASK Reference 5.63 (3.49, 9.10) 19.26 (11.75, 31.57) 34.60 (19.76, 60.58)
MDRD Reference 2.18 (1.60, 2.99) 2.87 (2.06, 4.00) 4.47 (3.14, 6.37)
MMKD Reference 1.77 (0.23, 13.82) 4.03 (0.54, 30.23) 4.30 (0.58, 31.74)
Overall Reference 3.18 (1.40, 7.18) 6.38 (1.34, 30.34) 9.47 (1.81, 49.60)
Dipstick category
/± + ++ +++
Kaiser Permanente Northwest Reference 1.71 (0.76, 3.84) 7.22 (4.21, 12.97) 19.41 (11.06, 34.04)
Overall Reference 2. 92 (2. 08, 4. 10) 7. 70 (4. 52, 13. 10) 15. 01 (8. 36, 26. 95)
Abbreviations: AASK, African American Study of Kidney Disease and Hypertension; CRIB, Chronic Renal Impairment in Birmingham; MASTERPLAN, Multifactorial Approach and
Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practitioner; MDRD, Modification of Diet in Renal Disease; MMKD, Mild to Moderate Kidney Disease Study;
REIN, Ramipril Efficacy in Nephropathy; REIN 2, Ramipril Efficacy in Nephropathy 2; Steno, Steno Type 1 Diabetes Study.
aAdjusted for age, sex, race, previous cardiovascular disease, smoking status, diabetes mellitus, systolic blood pressure, and serum total cholesterol concentration.
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reflect clinically important inconsistencies in relative risks, as
shown in the forest plots.
The incidence rates of death and ESRD were of roughly
similar magnitude within most studies. This differs substan-
tially from the general population, in which the incidence
rate of death is at least 10 times higher than the incidence rate
of ESRD.20 This difference may be due to a higher inci-
dence of ESRD among individuals selected for CKD than
individuals with CKD in the general population, which
reduces the influence of the competing risk of mortality when
studying incident ESRD. This emphasizes the differences in
competing risk for ESRD and mortality, as well as other
outcomes, in different study populations.
Lower eGFR and higher albuminuria were much more
strongly associated with ESRD than with mortality.
Decreased GFR and albuminuria are primary factors in
the development of ESRD, whereas numerous comorbid
conditions may affect the risk of mortality in these study
participants. The much higher incidence of ESRD, relative to
the incidence of death in these CKD cohorts, reduces the
impact of the competing risk of death and may allow the
direct associations between eGFR and albuminuria with
ESRD to be observed more accurately than in the general
population. These analyses of individuals with CKD also
include a much higher proportion of deaths that occurred
after ESRD than studies in the general population. Another
factor to consider is the selection of participants for the
studies included in this meta-analysis. Individuals with
relatively high eGFR and/or low albuminuria, who are
enrolled in these studies, likely have more severe comorbid
conditions than most individuals with similar eGFR and
albuminuria included in general population studies. If these
comorbid conditions put the enrolled participants at higher
risk of death, the observed associations of eGFR and
albuminuria with mortality could be substantially con-
founded. These comorbid conditions may be less strongly
associated with progression to ESRD and, therefore, would
have less impact on the observed associations of eGFR and
albuminuria with ESRD.
The populations of the participating studies comprise
highly selected patients, with the majority enrolled in
a randomized clinical trial or referred to a nephrol-
ogist.6–8,10,14–17 The others are comprised of patients selected
from clinical populations because of decreased eGFR or
albuminuria.11 There were no obvious differences in the HRs
relating either eGFR or albuminuria with the risk of either
outcome according to whether the study was a randomized
trial or an observational study, although the baseline
characteristics and resultant incidence rates of both outcomes
varied widely and the number of studies within each category
was small, limiting the usefulness of formal meta-regression
models. Within observational studies, differences in study
populations may also exist between those with protocol-
driven study visits (CRIB (Chronic Renal Impairment in
Birmingham), NephroTest, and Mild to Moderate Kidney
Disease (MMKD)) and those based on administrative data
(British Columbia, Grampian ACR and Grampian PCR, and
Kaiser Permanente Northwest) or passive surveillance of
clinical events (Steno). Among the studies included in this
meta-analysis, those with protocol-driven examinations had
higher incidence of ESRD than those based on administrative
data. In addition, the incidence of ESRD was higher than the
incidence of mortality among studies with protocol-driven
examinations, whereas the incidence rates for these two
outcomes were more similar among studies based on
administrative data. We hypothesize that these differences
are due to the differing selection criteria used to enroll
participants in these two types of studies, such that studies
with protocol-driven examinations would more likely enroll
individuals with more severe disease and/or more comor-
bidities, whereas studies based on administrative data would
be more likely to enroll all individuals eligible based on a
limited number of easily identified diagnostic or laboratory
criteria. Despite the differences in ESRD incidence rates, we
did not observe any consistent differences in the strength
of the associations of eGFR and ACR with both outcomes
(that is, mortality and ESRD) across study types.
We acknowledge that this meta-analysis has limitations.
First, we did not perform a systematic literature search to
identify all potentially eligible cohorts. However, study
selection was unbiased with respect to the associations of
interest, and most of the included cohorts had not reported
or investigated these associations before we performed our
pooled analysis. Selection bias is therefore unlikely. Our
analyses do not assess changes in eGFR, albuminuria, or
covariates over time. Any bias from systematic differences in
changes in the predictors after baseline, however, would
presumably attenuate the associations between baseline
predictors and outcomes. No data could be taken into
account on the effects of treatment that was started during
follow-up. Therefore, it cannot be excluded that the observed
associations are influenced by the start of specific treatments.
However, if such treatment is effective in preventing
mortality and ESRD, as expected, then it would be expected
to lead to an underestimation of the true relative risk of low
eGFR and high albuminuria for these outcomes. There were
no obvious differences in the associations by the proportion
of diabetic individuals in the studies. However, it is
difficult to isolate any effect modification by diabetes in this
meta-analysis, as diabetic and non-diabetic participants
were not analyzed separately, and the participating studies
differed with respect to other inclusion and exclusion criteria
as well.
Our findings have important implications for clinical
practice and research in CKD. Traditionally, prognosis in
CKD is based on the clinical diagnosis (cause and pathology)
of CKD. Our findings that a higher level of albuminuria
and lower level of eGFR increase the risk for mortality and
ESRD consistently across cohorts, with diverse clinical
diagnosis in diverse settings, suggest that these measures
provide important prognostic information beyond clinical
diagnosis and should be considered in predicting prognosis.
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We acknowledge that the levels of eGFR and albuminuria
among patients with CKD are likely to vary according to
the clinical diagnosis and referral pattern. For example,
patients with lower eGFR and higher albuminuria are likely
to be younger and have primary kidney diseases, such as
glomerular, tubulointerstitial, or cystic kidney diseases,
whereas those with higher levels of eGFR or lower levels of
albuminuria may be older and have kidney disease due to
systemic vascular disease, such as hypertension or diabetes.
Similarly, the risk for ESRD or mortality likely varies across
clinical diagnosis of CKD and referral pattern, as well as by
the level of albuminuria and eGFR. The risk for these
outcomes is also influenced by age, sex, race, cardiovascular
disease (CVD) risk factors, and history of CVD. On the basis
of our results, it seems likely that prognosis is determined by
all these factors, and development of risk prediction models
and scores for these outcomes will need to take all these
factors into account. Future studies should also consider the
influence of clinical diagnosis and level of eGFR and
albuminuria on the risk of concurrent complications of
CKD, such as hypertension, anemia, malnutrition, bone and
mineral disorders, and electrolyte disorders, as well as for
prognosis related to other outcomes associated with CKD,
such as infection or cognitive impairment.
In conclusion, we found that lower eGFR and more severe
albuminuria independently predict mortality and ESRD
among individuals with CKD. The observed associations
provide evidence consistent with the use of eGFR stages in
classification of CKD and suggest that addition of albumi-
nuria stages may provide additional prognostic information
among individuals with CKD.
MATERIALS AND METHODS
Study selection
Studies were identified by the planning committee and analytic team,
and discussion between collaborators. This was enhanced by a call for
participation at the World Congress of Nephrology in Milan (May,
2009), a published position statement of KDOQI (Kidney Disease
Outcomes Quality Initiative) and KDIGO,5 and an announcement on
the KDIGO website (http://www.kdigo.org). To be eligible for
inclusion in this meta-analysis, studies had to include primarily
participants selected because of CKD, provide information at baseline
on estimated or measured GFR and either urinary albumin or urinary
protein excretion, and include at least 50 ESRD events or deaths to
ensure sufficient outcomes in the reference cell. The definitions of
CKD used in each study are available in the specific references.
Individuals with ESRD were excluded from all studies.
Study variables
eGFR was calculated using the Modification of Diet in Renal Disease
(MDRD) Study equation using age, sex, race, and serum creatinine
concentration.1,21 Each participating study group was asked to
standardize the serum creatinine measurements to isotope dilution
mass spectrometry-traceable methods, but calibration was not
uniform. Albuminuria was assessed as the urinary ACR or urinary
PCR, preferably measured in a first morning void urine sample.
If first morning voids were not available, spot urine samples or
samples from 24-h urine collections were used. In studies in which
no quantitative albuminuria measurements were available, data on
dipstick proteinuria were collected.
History of CVD was defined as previous myocardial infarction,
bypass grafting, percutaneous coronary intervention, heart failure, or
stroke. Hypertension was defined as systolic blood pressure
X140mmHg or diastolic blood pressure X90mmHg or use of
antihypertensive medication. Hypercholesterolemia was defined as
total cholesterolX5.0mmol/l in the case of a positive history of CVD
and asX6.0mmol/l in the case of a negative history of CVD. Diabetes
mellitus was defined as fasting glucose X7.0mmol/l or non-fasting
glucose X11.1mmol/l or use of glucose-lowering drugs, or, if other
data were not available, self-reported diabetes. Smoking status was
dichotomized as current versus not current smoking. ESRD was
defined as the start of renal replacement therapy or death due to
decreased kidney function and not due to acute kidney injury. All
deaths occurring before or after ESRD were included in the analyses.
The clinical diagnosis (cause and pathology) of CKD was not
included because it was not ascertained in all studies and it was not
ascertained uniformly across studies in which it was recorded.
Statistical analysis
The primary objective of this study was to evaluate the independent
associations of eGFR and albuminuria with the risk of all-cause
mortality and ESRD. Investigators from each study newly analyzed
their data following an a priori analytic plan using standard
statistical programs supplied by the central analysis team. All
analyses were conducted using Stata version 10 or 11 (Stata, College
Station, TX), SAS version 9 (SAS Institute, Cary, NC), or R version
2.9.2 (R Foundation for Statistical Computing, Vienna, Austria).
Categories were created for eGFR (15–29, 30–44, 45–74, 75–89,
90–104, andX105ml/min per 1.73m2), ACR (o30, 30–299, 300–999,
andX1000mg/g), PCR (o50, 50–499, 500–1499, andX1500mg/g),
and dipstick proteinuria (negative/trace, þ , þ þ , and Xþ þ þ ).
As to be expected for CKD cohorts, limited data were available for
eGFR categories above 74ml/min per 1.73m2; hence, these results are
not shown. Cox proportional hazards models were used to obtain
adjusted HRs for each category of eGFR relative to the reference
group of 45–74ml/min per 1.73m2, and for each category of ACR/
PCR/dipstick proteinuria (using the lowest category for each as the
reference) (Supplementary Appendix S2 online). A broad eGFR
reference group was chosen because several studies had no events or
few events in the narrower ranges of eGFR 60–74 or 45–59ml/min per
1.73m2. These models were adjusted for age, sex, race, history of
CVD, smoking status, diabetes mellitus, systolic blood pressure, and
serum total cholesterol concentration, wherever data were available.
Cox proportional hazards models were also constructed with log ACR
or log PCR, and eGFR, modeled as continuous variables, adjusted for
all the covariates in the categorical analysis. When log ACR or log
PCR are modeled as linear terms, results are presented for an
eightfold higher ACR or PCR. eGFR was modeled as a linear spline
with knots at 45, 60, 75, 90, and 105ml/min per 1.73m2. As data were
limited at the higher eGFR ranges, results are presented for 15ml/min
per 1.73m2 lower eGFR below 45ml/min per 1.73m2. Data from
specific studies were excluded from specific analyses if the range of
values included in the study did not allow HRs to be estimated (for
example, all ACR values4300mg/g) or if the study had no events in
the reference category.
Pooled estimates of the HR and 95% CI were obtained from a
random effects meta-analysis. Heterogeneity was estimated using the
w2-test for heterogeneity and the I2 statistic.22 Meta-analyses were con-
ducted separately for studies with ACR and PCR. The Grampian cohort
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included ACR data on some participants and PCR data on other
participants. These were treated as two separate studies in the analyses.
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